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As raised by Ammirati et al. (1) the recent evidence (2) that prevalence of silent cerebral ischemia 
(SCI) in patients with paroxysmal and persistent atrial fibrillation (AF) and controls in sinus rhythm 
implies several clinically relevant issues. 
The finding that approximately half of controls presented at least an area of SCI is strongly 
hypothesis generating. On the other side the prevalence of other cardio-embolic sources, as patent 
foramen ovale or nonstenotic carotid plaques material, should not be differently stratified within 
cases and controls, therefore not biasing main study results.  
Indeed the question whether SCI represent a target for oral anticoagulation (OAC) to prevent 
cognitive impairment is crucial. In fact,  risk stratification, to date, relies on clinical scores 
(CHA2DS2-VASc score) based on symptomatic cerebral events only and, anyway, fallacious. 
The occurrence of cerebrovascular events in AF patients, despite low risk score remains 
unfortunately not unusual (3) warranting introduction of “new” markers, as left atrial appendage 
morphology (4,5) and specific echocardiographic parameters (6). Limited literature has assessed 
whether antiaggregants/OAC may prevent/reduce SCI. One small study (7) suggested that aspirin 
attenuates SCI incidence in AF patients, preventing events also in early stages of AF-related 
cerebral damage and, consequently, cognitive decline. However, this option is not recommended 
due to the detrimental effects of antiaggregants wih bleeding (8). We fully agree with Ammirati et 
al that further prospective randomized trials are ne ded to evaluate the possible reduction of SCI by 
OAC. In the meantime aggressive rhythm control strategy is mandatory to prevent clinical and 
silent cerebral ischemia by sinus rhythm restoration and maintenance.  
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